Annual Report 2024

CHAIRMAN’S STATEMENT 7 The United Laboratories International Holdings Limited Annual Report 2024 Keeping on innovation and R&D In 2024, to promote the high-quality transformation of the pharmaceutical industry, the State Council issued the “Implementation Plan for Whole-Chain Support for the Development of Innovative Drugs”, enhancing the support for the research and development, clinical trials and market access of innovative drugs. In particular, in terms of market access, 38 new global innovative drugs were added to the “National Drug List for Basic Medical Insurance, Occupational Injury Insurance and Maternity Insurance (2024 Edition)”, with the number and proportion hitting record highs. In active response to the national strategy, the Group has continued to increase its investment in R&D in the past year, and made positive progress in the R&D of new drugs, products registration and approval and consistency evaluation of the quality and efficacy of generic drugs. During the year, the Group continued to increase its investment in R&D and at the same time enhanced its R&D efficiency. The R&D and clinical study of innovative drugs were promoted in an orderly manner. The Group has 8 Class 1 new drug projects in the clinical stage, including a number of blockbuster products with high market value. The Group’s self- developed Class 1 innovative drug UBT251 Injection has been approved for clinical trials in China and the United States for multiple indications, and several other new drug development and clinical trials have made positive progress. We will also continue to enrich the layout of new drug pipelines, improve the configuration of high-end talent teams, accelerate the development and commercialization of new drugs, and continuously enhance the competitiveness and creativity of the Group. At the same time, the Group is also actively planning and promoting the licensing-out of new drug projects, and is committed to providing more comprehensive treatment options and medication choices for patients around the world. The Group continues to deepen its global strategic layout and enhance the innovative influence of The United Laboratories. Crafting new growth points through new business ventures and enhanced capabilities As the market environment changes and competition intensifies, it is particularly important to expand our business portfolio and create a second growth curve. The diversified business portfolio will help enhance the Group’s overall competitiveness and strengthen the Company’s market leadership and brand value. In view of the aging of the population and the growing demand for healthcare consumption, the Group established the Big Health Division during the year, which has deployed five major product lines: general dietary supplements, healthcare food products, cross- border nutritional supplements, medical devices, and medical and aesthetic skincare products. Currently, we have marketed 18 products, covering categories such as bone and joint nutrition, intestinal regulation, cardiovascular health, vision protection and immunity enhancement. Based on the strategy of “omni-channel, omni-domain, and omni-population”, we have built a matrix of e-commerce, live broadcasting and new retail online platforms, while deepening the coverage of pharmacy chains and health vertical channels. The Group is committed to continuously establishing iconic brands in the health consumption sector.